450839-40-4

物理化学性质
沸点722.0±60.0 °C(Predicted)
密度1.29±0.1 g/cm3(Predicted)
储存条件-20°C, protect from light
溶解度Acetonitrile: Slightly soluble: 0.1-1 mg/ml
DMSO: Sparingly soluble: 1-10 mg/ml
DMSO: Sparingly soluble: 1-10 mg/ml
酸度系数(pKa)12.15±0.29(Predicted)
形态Solid
颜色White to off-white
ABT-100价格(试剂级)
报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
2025/05/22 | HY-119257 | ABT-100 | 450839-40-4 | 1 mg | 1000元 |
2025/05/22 | HY-119257 | ABT-100 ABT-100 | 450839-40-4 | 5mg | 3600元 |
2025/05/22 | HY-119257 | ABT-100 ABT-100 | 450839-40-4 | 10 mg | 5580元 |
常见问题列表
生物活性
ABT-100 是一种有效的,高选择性和口服活性的 farnesyltransferase 抑制剂。ABT-100 抑制细胞增殖 (对于 EJ-1,DLD-1,MDA-MB-231,HCT-116,MiaPaCa-2,PC-3 和 DU-145 细胞的 IC50 分别为 2.2 nM,3.8 nM,5.9 nM,6.9 nM,9.2 nM,70 nM 和 818 nM),可增加细胞凋亡并减少血管生成。ABT-100 具有广谱抗肿瘤活性。靶点
Farnesyltransferase
体外研究
ABT-100 (0.1-100 nM; 7 days; EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells) treatment shows dose-dependent growth inhibition of human cancer cell lines. Also inhibits colony formation at concentrations comparable with which ABT-100 inhibits anchorage-dependent growth.
Cell Proliferation Assay
Cell Line: | EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells |
Concentration: | 0.1-100 nM |
Incubation Time: | 7 days |
Result: | Demonstrated dose-dependent growth inhibition of human cancer cell lines. |
体内研究
ABT-100 (6.25-12.5 mg/kg/day; subcutaneous injection; daily; for 21 days; C.B-17 scid male mice) treatment regresses EJ-1 tumors in mice.
Animal Model: | C.B-17 scid male mice with EJ-1 cells |
Dosage: | 6.25 mg/kg/day, 12.5 mg/kg/day |
Administration: | Subcutaneous injection; daily; for 21 days |
Result: | Regressed EJ-1 tumors in C.B-17 scid male mice. |